1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
A disease with two faces? Re-naming ME/CFS
Persuasion Smith covers the bases on the misleading and disreputable name for our disease we've all been saddled with ...
Discuss the article on the Forums.

New warning on Rituximab

Discussion in 'Other Health News and Research' started by MeSci, Sep 27, 2013.

  1. MeSci

    MeSci ME/CFS since 1995; activity level 6

    Cornwall, UK
    Just seen on Physician's First Watch:

    FDA Adds Boxed Warning to Two Cancer Drugs
    By the Editors

    The labels of the immune-suppressing, anti-cancer drugs ofatumumab (Arzerra) and rituximab (Rituxan) will be updated with a boxed warning noting an increased risk for reactivation of hepatitis B virus infection. Rituximab is used to treat non-Hodgkin lymphoma, and both drugs are used for chronic lymphocytic leukemia.

    In its MedWatch safety alert, the FDA offers guidance for clinicians to help decrease the risk for HBV reactivation with these agents.

    FDA MedWatch safety alert (Free) http://click.jwatch.org/cts/click?q=227%3B67896262%3BzeBeGPRQRwWxrV7BojPq0%2FwzDWmDRFf98ZoSAu1SKQQ%3D
    Background: NEJM Journal Watch summary on HBV reactivation after rituximab (Your NEJM Journal Watch registration required) http://click.jwatch.org/cts/click?q=227;67896262;zeBeGPRQRwWxrV7BojPq09FCdigMlZPW8ZoSAu1SKQQ=
    Simon likes this.

See more popular forum discussions.

Share This Page